Adalimumab is traded in names such as Exemptia and Humira are medication used for treating psoriatic arthritis, Crohn’s disease, rheumatoid arthritis, psoriasis and ulcerative colitis. Adalimumab generally binds with tumor necrosis factor-alpha (TNFα). TNFα when binds to a TBFα receptors leads to inflammatory response to autoimmune disease. Thus binding an adalimumab to a TNFα reduces the chance of inflammatory response.Rising cases of arthritis is one of the most major drivers of the adalimumab market globally. Cases of women suffering from arthritis are more often in old age owing to loss of calcium in body. Moreover rheumatoid arthritis can also be genetically inherited making it a more obvious cause of arthritis in human body. Thus the above mentioned reason owes towards the growth of adalimumab market.
However, adalimumab market face a challenge pertaining to its high cost, which could cost approximately 2000 – 3000 US$ per month. Moreover, while the countries in North America and Europe is already ahead of other nations such as Asia Pacific and Rest of the World has also led to the slowdown of the global adalimumab market due to lack of its adoption due to high cost associated with it.
The implications of adalimumab are majorly on the people suffering with arthritis, Crohn’s disease and ulcerative colitis as they are the direct customers in the market. Segmentation based on disease type includes the psoriatic arthritis, Crohn’s disease, rheumatoid arthritis, psoriasis and ulcerative colitis. Currently the rheumatoid arthritis sub-segment accounts for the largest market and is estimated to be growing at a high pace. Factors such as sedentary lifestyle and genetics have led to the growth arthritis and psoriasis in the global adalimumab market.
Moreover, adalimumab is generally used in autoimmune disease where the body immune system performs abnormally against substances and tissues present in the body. With the rapidly developing nations such as India, South Korea, Saudi Arabia, South Africa and Brazil among others, the demand for adalimumab is expected to escalate at a substantial pace due to the growing autoimmune disease in these regions. Owing to the growing prevalence of rheumatoid arthritis globally many people are facing joint pains. Thus in turn the demand for adalimumab is estimated to observe significant growth in future.
The major drivers of the adalimumab market is owing to the surge in global arthritis level and psoriasis due to autoimmune deficiency, the consumption of adalimumab has considerably increased and is going to remain high during the forecast period. Moreover, the market is consolidated with the presence very few players offering bio similar products at very reasonable price, thus creating an intense competition among the players in the adalimumab market.
A recent market trend suggested that the North America and Europe region due availability of well-structured regulatory framework, reimbursement coverage and better healthcare infrastructure is driving the market.
Countries such as the U.S., Canada, the U.K, and Germany among others have observed immense growth of adalimumab market in the past decades due to the rising relevance of arthritis cases arising in these regions due to sedentary lifestyle.
North America is estimated to be the largest market for adalimumab market currently, followed by Europe. Asia Pacific is currently estimated to be most lucrative region in the global adalimumab market.
Currently the major player of the adalimumab market is Abbott Laboratories. However, after the split of Abbott laboratories into two companies in 2013, Humira is now the product of AbbVie. In India adilumumab’s bio similar was launched under the name of Exemptia by Cadila Healthcare Ltd. Some of the major players of the adalimumab market are Amgen, Pfizer, Mylan N.V., Novartis AG, AbbVie, and Boehringer Ingelheim GmbH among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.